Abstractbeiträge (selektiert)

C. Dings, T. Lehr. Pharmacokinetic and Pharmacodynamic Modeling of Acetylsalicylic Acid and its Major Metabolite Salicylic Acid. 25th Population Approach Group Europe (PAGE), June 2016, Lisboa, Portugal

N. Scherer, C. Dings, M. Böhm, U. Laufs, T. Lehr. Pharmacokinetic and Pharmacodynamic Modeling of Alirocumab and Evolocumab, two fully human monoclonal antibodies targeting PCSK9. 25th Population Approach Group Europe (PAGE), June 2016, Lisboa, Portugal

J.G. Wojtyniak, J. Liebl, T. Lehr. A cancer cell cycle model to predict effects of combination therapy and different dosing schedules on cell cycle, tumor growth and therapy outcome. 25th Population Approach Group Europe (PAGE), June 2016, Lisboa, Portugal

H. Britz, D. Moj, N. Hanke, T. Lehr. Physiologically-Based Pharmacokinetic (PBPK) Modeling of the Dronedarone Drug-Drug Interaction with Digoxin. 25th Population Approach Group Europe (PAGE), June 2016, Lisboa, Portugal

D. Lott, J. Dingemanse, T. Lehr, A. Krause. Population pharmacokinetics of the selective S1P1 receptor modulator ponesimod. 25th Population Approach Group Europe (PAGE), June 2016, Lisboa, Portugal

N. Hanke, S. Frechen, H. Britz, D. Moj, T. Kanacher, T. Eissing, T. Wendl, T. Lehr. Physiologically-based Pharmacokinetic Modeling of Rifampin Drug-Drug Interactions with Midazolam and Digoxin. 25th Population Approach Group Europe (PAGE), June 2016, Lisboa, Portugal

M.I. Titze, O. Schaaf, M. H. Hofmann, M. Sanderson, S. Zahn, J. Quant, T. Lehr. Allometric scaling of the pharmacokinetics of BI 893923, a novel IGF-1 receptor inhibitor. CESAR Annual Meeting, September 2015, Innsbruck, Austria

N. Schaefer, J.G. Wojtyniak, M. Kettner, J. Schlote, M.W. Laschke, A.H. Ewald, T. Lehr, M.D. Menger, H.H. Maurer, P.H. Schmidt. Pharmacokinetic modelling of JWH-10, RCS-4, and THC in pig serum after intravenous administration. Annual Meeting of The International Association of Forensic Toxicologists (TIAFT), August 2015, Firenze, Italy

M.I. Titze, O. Schaaf, M. H. Hofmann, M. Sanderson, S. Zahn, J. Quant, T. Lehr. PK/PD modeling of biomarker modulation and tumor growth inhibition by BI 893923, a novel IGF-1 receptor inhibitor. 24th Population Approach Group Europe (PAGE), June 2015, Hersonissos, Greece

D. Moj, A. Schäftlein, N. Hanke, W. Braun, M.J. Müller, T. Lehr. Is the ICRP reference man still suitable for physiologically-based pharmacokinetic (PBPK) modeling? 24th Population Approach Group Europe (PAGE), June 2015, Hersonissos, Greece

D. Lott, J. Dingemanse, M. Hoch, T. Lehr, A. Krause. Population pharmacokinetics of the selective S1P1 receptor modulator ponesimod and its primary metabolites in healthy and organ-impaired subjects. 24th Population Approach Group Europe (PAGE), June 2015, Hersonissos, Greece

C. Dings, A. Schäftlein, T. Lehr. Predicting the impact of oral anticoagulants on the human coagulation pathway using a comprehensive systems pharmacology model.  Annual meeting of the German Pharmaceutical Society (DPhG) 2014, Frankfurt, Germany

Schäftlein, H. Maas, P. A. Reilly, A. Staab, T. Lehr. Population modeling of the relationship between the pharmacokinetics of the oral thrombin inhibitor dabigatran etexilate and coagulation biomarkers in patients with non-valvular atrial fibrillation from the RE-LY trial. 23nd Population Approach Group Europe (PAGE), June 2014, Alicante, Spain

M.I. Titze, M. Ehrhardt, S. Smola, N. Graf, T. Lehr. A semi-mechanistic model to describe the bidirectional interaction between oncolytic reovirus and in vitro tumor growth of U87-glioblastoma cells. 23nd Population Approach Group Europe (PAGE), June 2014, Alicante, Spain

D. Moj, T. Kanacher, T. Wendl, S. Willman, T. Lehr. Physiologically-based Pharmacokinetic (PBPK) modeling of the time-dependent drug-drug interaction (DDI) of clarithromycin and midazolam. 23nd Population Approach Group Europe (PAGE), June 2014, Alicante, Spain

D. Moj, K. Thelen, S. Willman, T. Lehr. Physiologically-based pharmacokinetic (PBPK) model of clarithromycin Annual meeting of the German Pharmaceutical Society (DPhG) 2013, Freiburg, Germany

M.I. Titze, M. Ehrhardt, S. Smola, N. Graf, T. Lehr. A semi-mechanistic mathematical model to describe the effect of oncolytic reovirus on in vitro tumor cell growth of U87-glioblastoma cells Annual meeting of the German Pharmaceutical Society (DPhG) 2013, Freiburg, Germany

K. Dietel, T. Gampfer, J. Stingl, T. Lehr. Personalized pharmacotherapy through pharmacogenetic testing in Germany – Obstacles and opportunities Annual meeting of the German Pharmaceutical Society (DPhG) 2013, Freiburg, Germany

Schneider, H. Britz, M.I. Titze, T. Lehr. A study to assess the accuracy and precision of the digitizing software GetData Graph Digitizer Annual meeting of the German Pharmaceutical Society (DPhG) 2013, Freiburg, Germany

J.D. Gómez-Mantilla, U.F. Schaefer, T. Lehr, V.G. Casabó, C.M. Lehr. Tailor-made dissolution profile comparisons using in vitro-in vivo correlation models. 22nd Population Approach Group Europe (PAGE), June 2013, Glasgow, Scotland

K.H. Liesenfeld, A. Staab, S. Haertter, S. Formella, A. Clemens, T. Lehr. Pharmacometric Characterization of the Elimination of Dabigatran by Haemodialysis.  22nd Population Approach Group Europe (PAGE), June 2013, Glasgow, Scotland

K.G. Haug, A. Staab, T. Lehr. Development and Validation of a Semi-Physiological Model of Amyloid-β Biosynthesis and Clearance in Human Cerebrospinal Fluid Including the Impact of the Gamma-Secretase Inhibitor Semagacestat. Annual Meeting ASCPT. March 2013, Indianapolis, USA

K.H. Liesenfeld, T. Lehr, V. Moschetti, S. Formella, A. Clemens, A. Staab, S.Haertter.  Modelling and simulation of redistribution of dabigatran after elimination by haemodialysis in patients with end stage renal disease (ESRD).  XXIII Congress of the ISTH, July 2011, Kyoto, Japan

K.H. Liesenfeld, T. Lehr, V. Moschetti, S. Formella, A. Clemens, A. Staab, S.Haertter.  Modeling and simulation to optimise the study design investigating the hemodialysis of dabigatran in patients with end stage renal disease (ESRD).  20th Population Approach Group Europe (PAGE), June 2011, Athens, Greece

T. Lehr, H.G. Schaefer, A. Staab. High-throughput genotyping data joins pharmacometric analysis: An algorithm for the successful integration Annual meeting of the American Association of Pharmaceutical Scientists (AAPS), November 2009, Los Angeles, CA, USA

Dansirikul, A. Staab, L. Salin, S.Haertter, T. Lehr.  Population pharmacokinetic analysis of pramipexole extended-release formulation in Parkinson’s Disease (PD) patients.  18th Population Approach Group Europe (PAGE), June 2009, St. Petersburg, Russia

R. Hauser, O. Rascol, P. Barone A.Schapira, W. Powe, Y. Mizuno, C. Dansirikul, A. Staab, T. Lehr, S.Haertter.  Pharmacokinetic Profiling of Pramipexole Extended-Release in Parkinson’s Disease (PD): Implications for Dosing in PD Patients With Renal Insufficiency.  13th International Congress of Parkinson's Disease and Movement Disorders, June 2009, Paris, France

Dansirikul, R. Hauser, A. Staab, T. Lehr, S.Haertter.  Population pharmacokinetic analysis of pramipexole extended-release formulation in patients with Parkinson’s Disease.  61st American Academy of Neurology (AAN) Annual Meeting, May 2009, Seattle, Washington, USA

T. Lehr, A. Staab, C. Tillmann, D. Trommeshauser, A. Raschig, H.G. Schaefer, C. Kloft.  Efficacy modelling of NS2330 in mild Alzheimer’s disease patients.  15th Population Approach Group Europe (PAGE), June 2006, Brugge, Belgium

T. Lehr, A. Staab, C. Tillmann, D. Trommeshauser, A. Raschig, H.G. Schaefer, C. Kloft.  Population pharmacokinetics of NS2330 and its major metabolite in Alzheimer’s disease patients. 15th Population Approach Group Europe (PAGE), June 2006, Brugge, Belgium

Zeumer, A. Staab, T. Lehr, C. Tillmann, K.H. Liesenfeld, H.G. Schaefer.  PROPHET - A convenient and efficient environment for the use of NONMEM in a global pharmaceutical company.  15th Population Approach Group Europe (PAGE), June 2006, Brugge, Belgium

T. Lehr, C. Tillmann, A. Staab, D. Trommeshauser, H.G. Schaefer, C. Kloft:  Estimating the maximum impact of CYP3A4 inhibition on the pharmacokinetics of long half-life drugs: a mechanistic modelling approach Annual meeting of the American Association of Pharmaceutical Scientists (AAPS), November 2005, Nashville, TN, USA